ScholarLens Back to search
2007•Journal watchRequires access

ABVD Therapy Without G-CSF for Hodgkin Lymphoma: Further Evidence

Michael E. Williams

Open publisher page 0 citations

Abstract

ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) is standard therapy for patients with advanced Hodgkin lymphoma (HL), and it

About this research paper

What this paper is about

ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) is standard therapy for patients with advanced Hodgkin lymphoma (HL), and it

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) is standard therapy for patients with advanced Hodgkin lymphoma (HL), and it

Key concepts: ABVD, Medicine, Hodgkin lymphoma, Lymphoma, Oncology, Bleomycin, Dacarbazine, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
ABVD Therapy Without G-CSF for Hodgkin Lymphoma: Further Evidence — Research Paper | ScholarLens